Participated · Seed · Dec 2025

Ionic Wind is a St. Gallen–based spin-off from the Swiss Federal Laboratories for Materials Science and Technology (Empa) that creates cooling modules using high-voltage electric fields to move air without any mechanical parts. The solid-state design allows the cooling elements to be integrated directly into device housings, densely populated PCBs, or structural components, enabling quieter operation, higher reliability, and more compact product designs. Target applications include edge-AI systems, single-board computers, and industrial sensor modules that are bumping into thermal and spatial limitations with conventional fans. With fresh capital, the company plans to complete product certification, broaden its portfolio, and carry the solution through the final steps to market readiness. Mid-term, the technology could let hardware makers build more powerful, robust, and energy-efficient devices for the expanding edge-computing and industrial IoT markets. No revenue or user figures were disclosed in the article.

Participated · Seed · Sep 2025

a-metal AG, headquartered in the Technopark Zürich, is a spin-off from ETH Zürich and the University of Applied Sciences Northwestern Switzerland that builds a compact, low-cost, and easy-to-operate metal 3D printer aimed at lowering the cost and complexity barriers of metal additive manufacturing. The company positions its system as an ideal entry-level solution that eliminates the need for large, expensive equipment, specialized lab space, or expert personnel. With its technology already in pre-series production, a-metal intends to industrialize the printer, scale manufacturing, professionalize its market presence, and expand its team across customer support, operations, and software development. The firm emphasizes a plug-and-play experience to broaden metal AM adoption among small and medium-sized enterprises. New capital will accelerate the move from pilot builds to full commercialization. Although key financial metrics such as revenue or user count were not disclosed, the firm states that the fresh funding marks the beginning of its next growth phase. The strategy centers on converting early technical success into scalable production and widening market reach.

Participated · Seed · Sep 2025

PeriVision’s core product, the VisionOne platform, fuses standard VR goggles with advanced artificial-intelligence algorithms to perform visual field examinations that are faster and more comfortable than traditional hospital equipment. Aimed at the world’s 100 million glaucoma patients, the system has already obtained certifications in the EU, the US and the UK, and its first product has been commercially launched. The company plans to broaden VisionOne with new tests for retinal disorders, add AI-driven analytics tools and build deeper clinical-integration solutions. Over the past three years, PeriVision has augmented its development with multiple non-dilutive supports, including EIT Health Wild Card, two Innosuisse project grants, FIT credit, and placements in Switzerland’s TOP100 Startups and Venture Leaders Medtech 2023. The startup is also taking part in Innosuisse Scale-up Coaching and the Biopôle Vanguard Accelerator. With the fresh capital, PeriVision intends to accelerate market expansion across Europe, the United States and the United Kingdom through 2025.

Participated · Seed · Feb 2018

Pregnolia is a Zurich-based medical device company focused on obstetrics, specifically the early prediction of preterm birth through the measurement of cervical stiffness. Its handheld diagnostic device provides clinicians with a quantitative biomarker that early studies indicate is more reliable than current standard methods. Three recent peer-reviewed publications in leading journals have reinforced the validity of cervical stiffness as a predictor, bolstering the company’s scientific foundation. Pregnolia plans to use its technology to make cervical stiffness assessment part of routine prenatal care and is already working on an FDA approval strategy for the U.S. market. The company recently attracted competitive European Innovation Council (EIC) support, underscoring the perceived impact of its solution. Financially, Pregnolia has raised CHF 3.4 million (~$4.4 million) in its latest round, following a CHF 2.2 million round in 2023 that funded multi-country clinical studies. The new capital will fund further clinical validation and steps toward commercialization.